Scientist/Sr. Scientist, DMPK
tl;dr General Proximity is a seed-stage startup developing the next generation of induced proximity medicines (IPMs). Our OmniTAC drug discovery engine furnishes molecules that co-opt existing cellular machinery to overcome therapeutic challenges, which have remained unapproachable to other modalities for decades. We are seeking a first-rate DMPK expert to help us pioneer this uncharted frontier of drug discovery. Our Story A long-standing challenge in drug discovery is the development of molecules capable of modulating difficult or "undruggable" targets. Disease-causing proteins can be dysfunctional in many different ways, but our armamentarium for fixing them is quite limited. The most common mechanism of action for FDA-approved drugs is inhibition[1], but there are many other possible perturbation types whose potential remains unrealized. General Proximity is a seed-stage drug discovery company developing a novel platform technology to solve this problem. We make bifunctional drugs that induce the modification of drug targets by existing cellular machinery (rather than through direct modulation by the drug, the classical approach). Historically, the development of technologies that allow one to push new buttons in biology has been an incredibly fertile field for the discovery of new medicines[2, 3, 4], and our technology holds the same promise. The Position We are seeking an exceptional DMPK expert to join and lead our drug metabolism and pharmacokinetics function. This is a hands-on, high-impact role in which you will design and execute DMPK studies across our small molecule portfolio, interpret and communicate data to project teams, and serve as a key DMPK contributor in cross-functional settings. You will help shape scientific approaches, support regulatory activities, and play an important role in advancing programs from lead optimization through IND. You will work closely with our medicinal chemistry, structural biology, pharmac...